JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2023, 72(2):63-69 | DOI: 10.5817/CSF2023-2-63

Selective inhibitors of cyclooxygenase 2 - their past, present and future

Simona Valášková1, Ján Kyselovič1,2, Andrea Gažová3,*
1 V. interná klinika LF UK a Univerzitná nemocnica Bratislava, Nemocnica Ružinov Bratislava, Slovenská republika
2 Katedra farmakológie a toxikológie, Univerzita veterinárskeho lekárstva a farmácie Košice, Slovenská republika
3 Ústav farmakológie a klinickej farmakológie LF UK, Bratislava, Slovenská republika

Pain is a serious subjective experience, which, although it has a protective nature, it physically and mentally exhausts the patient. The pharmacological field of development and research in the treatment and relief of pain has been dynamic and interesting ever since the isolation of salicylic acid. After discovering the molecular nature of cyclooxygenase and its inhibition, research focused on selective COX-2 inhibitors, but they were a big disappointment. Today, the possibility of contributing to safe and effective analgesic-antiphlogistic treatment for the patient with a combination of drugs is emerging again.

Keywords: cyclooxygenase inhibition; non-steroidal anti-inflammatory drugs; coxibs

Received: February 1, 2023; Accepted: March 10, 2023; Published: February 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Valášková S, Kyselovič J, Gažová A. Selective inhibitors of cyclooxygenase 2 - their past, present and future. Čes. slov. farm. 2023;72(2):63-69. doi: 10.5817/CSF2023-2-63.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ghlichloo I., Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). StatPearls Publishing 2022.
    2. Ahn G.Y., Bae S.-C. Strategies for the safe use of non-steroidal anti-inflammatory drugs. J. Korean. Med. Assoc. 2018; 61, 367-375. https://doi.org/10.5124/jkma.2018.61.6.367 Go to original source...
    3. Bindu S., Mazumder S., Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020; 180, 114147. https://doi.org/10.1016/j.bcp.2020.114147 Go to original source... Go to PubMed...
    4. Fortune business insights. Non-steroidal Anti-Inflammatory Drugs [NSAIDs] Market Size By 2027 n.d. https://www.fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823 (30. 6. 2022).
    5. Kasciuškevičiūtė S., Gumbrevičius G., Vendzelytė A., Ščiupokas A., Petrikonis K., Kaduševičius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. Medicina 2018; 54, 30. https://doi.org/10.3390/medicina540200306. OECD. Health at a Glance 2021 - OECD n.d. https://www.oecd.org/health/health-at-a-glance/ (30. 6. 2022).
    6. NCZI. Zdravotnícka ročenka Slovenskej republiky 2021. Spotreba_liekov_a_zdravotnickych_pomocok_v_SR_2021_Sprava_k_publikovanym_vystupom.pdf (nczisk.sk)
    7. Gažová A., Kyselovič J. Známe a neznáme fakty o diklofenaku. Via practica 2017; 14(6), 311-312. www.solen.sk
    8. Lukáč J., Lukáčová O. Účinnosť a bezpečnosť koxibov. Ambulantná terapia 2007; 5(3-4), 192-198.
    9. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol. 1971; 231, 232-235. https://doi.org/10.1038/newbio231232a0 Go to original source... Go to PubMed...
    10. Rouzer C. A., Marnett L. J. Cyclooxygenases: structural and functional insights. J. Lipid Res. 2009; 50, S29-34. https://doi.org/10.1194/jlr.R800042-JLR200 Go to original source... Go to PubMed...
    11. Domper Arnal M.-J., Hijos-Mallada G., Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin. Drug Saf. 2022; 21, 373-384. https://doi.org/10.1080/14740338.2021.1965988 Go to original source... Go to PubMed...
    12. Ju Z., Li M., Xu J., Howell D. C., Li Z., Chen F.-E. Recent development on COX-2 inhibitors as promising antiinflammatory agents: The past 10 years. Acta Pharm. Sin. B. 2022; 12, 2790-2807. https://doi.org/10.1016/j.apsb.2022.01.002 Go to original source... Go to PubMed...
    13. Ahmadi M., Bekeschus S., Weltmann K.-D., von Woedtke T., Wende K. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med. Chem. 2022; 13, 471-496. https://doi.org/10.1039/D1MD00280E Go to original source... Go to PubMed...
    14. Szeto C.-C., Sugano K., Wang J.-G., Fujimoto K., Whittle S., Modi G. K., Chen C. H., Park J. B., Tam L. S., Vareesangthip K., Tsoi K. K. F., Chan F. K. L. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 69, 617-29. https://doi.org/10.1136/gutjnl-2019-319300 Go to original source... Go to PubMed...
    15. Masferrer J., Zweifel B., Manning P., Hauser S., Leahy K., Smith W., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994; 91, 3228-3232. https://doi.org/10.1073/pnas.91.8.3228 Go to original source... Go to PubMed...
    16. Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F., Burr A. M., Zhao W. W., Kent J. D., Lefkowith J. B., Verburg K. M., Geis G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284, 1247-1255. https://doi.org/10.1001/jama.284.10.1247 Go to original source... Go to PubMed...
    17. Malhotra S., Shafiq N., Pandhi P. COX-2 Inhibitors: A CLASS Act or Just VIGORously Promoted. MedGenMed2004; 6, 6.
    18. MERCK & CO.,INC. VIOXX®, Warning: Risk of serious cardiovascular and gastrointestinal events. www.accessdata.fda.gov, 2016.
    19. Lenzer J. FDA is incapable of protecting US "against another Vioxx." BMJ 2004; 329, 1253. Go to original source... Go to PubMed...
    20. Research C for DE and. Vioxx (rofecoxib) Questions and Answers. FDA 2018.
    21. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171, 1027-1028. https://doi.org/10.1503/cmaj.1041606 Go to original source... Go to PubMed...
    22. Heerdink E. R., Leufkens H. G., Herings R. M., Ottervanger J. P., Stricker B. H., Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med. 1998; 158, 1108-1112. https://doi.org/10.1001/archinte.158.10.1108 Go to original source... Go to PubMed...
    23. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. The Lancet 2004; 364, 1995-1996. https://doi.org/10.1016/S0140-6736(04)17523-5 Go to original source... Go to PubMed...
    24. EMA.www.ema.europa.eu/en/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_en.pdf
    25. El-Malah A. A., Gineinah M. M., Deb P. K., Khayyat A. N., Bansal M., Venugopala K. N., Aljahdali A. S. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals 2022; 15, 827. https://doi.org/10.3390/ph15070827 Go to original source... Go to PubMed...
    26. Schnitzer T. J., Burmester G. R., Mysler E., Hochberg M. C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C. J.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364, 665-674. https://doi.org/10.1016/S0140-6736(04)16893-1 Go to original source... Go to PubMed...
    27. Reed G. W., Nissen S. E. NSAID choice: lessons from PRECISION. Aging (Albany NY) 2019; 11, 2181-2182. https://doi.org/10.18632/aging.101930 Go to original source... Go to PubMed...
    28. Inova Health Care Services. NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease. clinicaltrials.gov; 2018.
    29. Kitov Pharma Ltd. A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy. clinicaltrials.gov; 2019.
    30. Chen W., Zhong Y., Feng N., Guo Z., Wang S., Xing D. New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases. Mol. Med. 2021; 27, 123. https://doi.org/10.1186/s10020-021-00358-4 Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.